{"id":"NCT01937598","sponsor":"Michael A. Nauck","briefTitle":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D","officialTitle":"Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2014-04","completion":"2015-06","firstPosted":"2013-09-09","resultsPosted":"2017-01-30","lastUpdate":"2017-01-30"},"enrollment":16,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Mixed meal test","otherNames":[]},{"type":"DRUG","name":"Liraglutide","otherNames":["Victoza"]},{"type":"DRUG","name":"Sitagliptin","otherNames":[]}],"arms":[{"label":"Sitagliptin, then Placebo","type":"EXPERIMENTAL"},{"label":"Placebo, then Sitagliptin","type":"EXPERIMENTAL"}],"summary":"Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with liraglutide and metformin","primaryOutcome":{"measure":"Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)","timeFrame":"0 to 300 min post mixed meal test","effectByArm":[{"arm":"Sitagliptin","deltaMin":5678,"sd":329},{"arm":"Placebo","deltaMin":5557,"sd":547}],"pValues":[]},"eligibility":{"minAge":"25 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":27},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Headache","Nausea","asympomatic hyppglycaemia"]}}